Acticor Biotech SAS Balance Sheet Health
Financial Health criteria checks 3/6
Acticor Biotech SAS has a total shareholder equity of €368.0K and total debt of €7.9M, which brings its debt-to-equity ratio to 2160.1%. Its total assets and total liabilities are €14.3M and €13.9M respectively.
Key information
2,160.1%
Debt to equity ratio
€7.95m
Debt
Interest coverage ratio | n/a |
Cash | €7.96m |
Equity | €368.00k |
Total liabilities | €13.93m |
Total assets | €14.30m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: ALACT's short term assets (€13.0M) exceed its short term liabilities (€8.6M).
Long Term Liabilities: ALACT's short term assets (€13.0M) exceed its long term liabilities (€5.3M).
Debt to Equity History and Analysis
Debt Level: ALACT has more cash than its total debt.
Reducing Debt: Insufficient data to determine if ALACT's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if ALACT has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ALACT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.